"I was first diagnosed I think I was 11 or 12."That was devastating for Scott Hedgpeth who has always loved being active and ...

Following the successful product launch of Zoryve, Arcutis Biotherapeutics has returned an impressive +200% year-to-date. Recent Q3 earnings impressed, with a blistering 452% year-over-year and 45 ...

Strategic appointments support further growth and position Company for future successWESTLAKE VILLAGE, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase ...

Arcutis Biotherapeutics (ARQT) announced several promotions to support further growth of Arcutis and the ZORYVE portfolio. Patrick Burnett, MD, ...

After a couple of days filled with investor nervousness, Arcutis Biotherapeutics has claimed FDA approval of Zoryve for the new indication of atopic dermatitis (AD), a common form of eczema.

The company's main current asset is its Zoryve franchise, also known as roflumilast. This compound comes in both form and gel form and garnered its first FDA approval in 2022. Zoryve is now ...

Arcutis Biotherapeutics' subsidiary, Arcutis Canada, has received Health Canada's approval for ZORYVE (roflumilast) topical ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical foam 0.3%, and $2.5M for ZORYVE cream 0.15% ...